Payment overview · 2025
General Payments
$2,077.77
131 reported records · 28 companies
Healthcare provider profile · identity verified
Ashley J Bennett, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOWLING GREEN, KY · NPI 1912905985
Verified facts
What the public records show
CMS Open Payments records show Ashley J Bennett, M.D. received $2,077.77 in general payments during 2025 across 131 reported records.
Novartis Pharmaceuticals Corporation accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $264.53 | 12.7% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $230.39 | 11.1% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $188.71 | 9.1% | 18 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $162.86 | 7.8% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.62 | 7.6% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $137.90 | 6.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.34 | 6.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.62 | 4.7% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.60 | 4.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.54 | 3.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.83 | 3.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $70.82 | 3.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.32 | 2.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.42 | 2.7% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $37.55 | 1.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.70 | 1.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $22.56 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.47 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.03 | 1.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.48 | 1.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.46 | 0.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.72 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.57 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.69 | 0.8% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.51 | 0.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.68 | 0.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.48 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.37 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,077.77 | 131 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $264.53 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $188.71 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $187.27 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $187.27 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $162.86 | 16 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $137.90 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $127.62 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $122.06 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.61 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.22 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $113.85 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.49 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $103.49 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $92.60 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $77.83 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $70.82 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $49.35 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $37.55 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.56 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 117 |
| Lisinopril | Lisinopril | 305 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 67 |
| Alendronate Sodium | Alendronate Sodium | 210 | 52 |
| Omeprazole | Omeprazole | 203 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 56 |
| Sertraline Hcl | Sertraline Hcl | 162 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 34 |
| Losartan Potassium | Losartan Potassium | 156 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 38 |
| Metformin Hcl Er | Metformin Hcl | 136 | 40 |
| Simvastatin | Simvastatin | 135 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 41 |
| Gabapentin | Gabapentin | 112 | 26 |
| Eliquis | Apixaban | 104 | 20 |
| Furosemide | Furosemide | 101 | 40 |
| Jardiance | Empagliflozin | 100 | 18 |
| Metformin Hcl | Metformin Hcl | 100 | 24 |
| Trazodone Hcl | Trazodone Hcl | 100 | 27 |
| Meloxicam | Meloxicam | 98 | 26 |
| Carvedilol | Carvedilol | 93 | 27 |
| Allopurinol | Allopurinol | 91 | 26 |
| Buspirone Hcl | Buspirone Hcl | 86 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 27 |
| Ozempic | Semaglutide | 83 | 19 |
| Montelukast Sodium | Montelukast Sodium | 79 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 25 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Januvia | Sitagliptin Phosphate | 70 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Famotidine | Famotidine | 62 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Glipizide Er | Glipizide | 57 | suppressed |
| Chlorthalidone | Chlorthalidone | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 19 |
| Bupropion Xl | Bupropion Hcl | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Synthroid | Levothyroxine Sodium | 49 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 14 |
| Armour Thyroid | Thyroid,pork | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Ramipril | Ramipril | 41 | 12 |
| Valsartan | Valsartan | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 16 |
| Atenolol | Atenolol | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 23 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Azithromycin | Azithromycin | 20 | 18 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Teriparatide | Teriparatide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Np Thyroid | Thyroid,pork | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Prednisone | Prednisone | 14 | 12 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,077.77 · 131 records | Novartis Pharmaceuticals Corporation | ABRYSVO, ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, ENTRESTO, EVENITY, FANAPT, FARXIGA, GEMTESA, HETLIOZ, Heplisav-B, INJECTAFER, JARDIANCE, JOURNAVX, KISUNLA, Kerendia, Korlym, LEQVIO, Leqembi, MOUNJARO, NP Thyroid 60, NUCALA, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, TAGRISSO, TONMYA, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error